Daklinza (daclatasvir) / BMS 
Welcome,         Profile    Billing    Logout  
 32 Diseases   5 Trials   5 Trials   1782 News 


12345678910111213...1314»
  • ||||||||||  velpatasvir (GS-5816) / Gilead, Daklinza (daclatasvir) / BMS
    Clinical, Journal, Real-world evidence, Real-world:  Real-World Experience, Effectiveness, and Safety of Direct-Acting Antivirals for the Treatment of Hepatitis C in Oman: A Cross-Sectional, Multicenter Study. (Pubmed Central) -  Dec 17, 2024   
    A cross-sectional study was conducted including 375 HCV patients with different genotypes, treated using different DAA regimens, with or without ribavirin, between January 2012 and December 2020 at the Sultan Qaboos University Hospital and the medical city for military and security services, two tertiary hospitals in Muscat, Oman...No significant adverse effects were reported. Based on our real-world experience, DAAs are highly effective in treating patients with HCV infection in Oman, with an excellent tolerability and safety profile.
  • ||||||||||  Journal:  Drug-induced hepatitis B virus reactivation: insights from FAERS database analysis. (Pubmed Central) -  Dec 4, 2024   
    According to the disproportionality analysis, the top five drugs with the highest ROR and PRR were daklinza, vocabria, doxorubicin, sovaldi, and ribavirin...Through an analysis of the FAERS database, it was observed that some pharmaceuticals do not adequately address the risk of HBV-R in their drug documentation. These findings could assist healthcare providers in promptly recognizing drug-induced HBV-R.
  • ||||||||||  Zepatier (grazoprevir/elbasvir) / Merck (MSD)
    Journal:  Validated LC/MS method for simultaneous determination of elbasvir and grazoprevir in human plasma. (Pubmed Central) -  Oct 26, 2024   
    The intra- and inter-day precision and accuracy of the quality control samples at low, medium, and high concentration levels exhibited relative standard deviations (RSD) < 15%, and the accuracy values ranged from 94.2% to 107.8%. The robustness of the method was established using a two-level full factorial design.
  • ||||||||||  Olysio (simeprevir) / J&J, Medivir, Daklinza (daclatasvir) / BMS
    PK/PD data, Journal:  Synchronous spectrofluorimetry and chemometric modeling: A synergistic approach for analyzing simeprevir and daclatasvir, with application to pharmacokinetics evaluation. (Pubmed Central) -  Apr 6, 2024   
    Moreover, the proposed models have been applied to determine the pharmacokinetics of simeprevir and daclatasvir, providing valuable insights into their distribution and elimination patterns. Overall, the study demonstrates the effectiveness of synchronous spectrofluorimetry coupled with multivariate calibration optimized by firefly algorithms in accurately determining and quantifying simeprevir and daclatasvir in HCV antiviral treatment, offering potential applications in pharmaceutical formulation analysis and pharmacokinetic studies for these drugs.
  • ||||||||||  Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Trial completion:  REVOLUTIOn: Antiviral Agents Against COVID-19 Infection (clinicaltrials.gov) -  Mar 22, 2024   
    P2/3,  N=256, Completed, 
    All patients will continue to be followed to SVR12. Active, not recruiting --> Completed
  • ||||||||||  Daklinza (daclatasvir) / BMS
    Journal:  Ser38-His93-Asn91 triad confers resistance of JFH1 HCV NS5A-Y93H variant to NS5A inhibitors. (Pubmed Central) -  Dec 20, 2023   
    The Ser38-His93-Asn91 triad in the dimer of the Y93H variant predicts a structural crash of the cleft receiving the NS5A inhibitor daclatasvir...However, NS5A-Y93H 1ZH1 alone could form dimer and conduct RNA replication in the absence of the 3FQM structure. In conclusion, this study provides novel insight into the functional significance of the Ser38-His93-Asn91 triad in resistance of the Y93H variant to NS5A inhibitors.
  • ||||||||||  Daklinza (daclatasvir) / BMS
    Journal:  Hepatitis C Retreatment With First-Line Direct Acting Antiviral Drugs. (Pubmed Central) -  Sep 11, 2023   
    P=N/A
    Sofosbuvir (S), daclatasvir (D), ledipasvir, or velpatasvir (V) containing first-line hepatitis C virus (HCV) treatment regimens fail to cure viremia in 5-10%...Two among three, in whom retreatment failed, achieved SVR12 following another course of sofosbuvir/velpatasvir/ribavirin for 24 weeks...HCV retreatment could be a treatment option if second-line anti-HCV drugs are not available. Successful retreatment could be achieved, in a large proportion, with the use of first-line drugs for 24 weeks with ribavirin
  • ||||||||||  Daklinza (daclatasvir) / BMS
    Journal:  Efficacy and Safety of Directly Acting Antivirals in Patients with Hepatitis C Infection on Hemodialysis. (Pubmed Central) -  Aug 31, 2023   
    Successful retreatment could be achieved, in a large proportion, with the use of first-line drugs for 24 weeks with ribavirin Sofosbuvir combination therapy offers an excellent response in dialysis patients irrespective of the genotype and presence of cirrhosis with minimal monitoring as in non-chronic kidney disease (CKD) patients.
  • ||||||||||  Daklinza (daclatasvir) / BMS
    Journal:  Sub-stoichiometric Modulation of Viral Targets-Potent Antiviral Agents That Exploit Target Vulnerability. (Pubmed Central) -  Aug 16, 2023   
    In this Viewpoint, we summarize the invention of the HIV-1 maturation inhibitor fipravirimat and discuss the emerging details around the mode of action of this class of drug that reflects inhibition of a protein composed of 1,300-1,600 monomers that interact in a cooperative fashion. Similarly, the HCV NS5A inhibitor daclatasvir has been shown to act in a highly sub-stoichiometric fashion, inhibiting viral replication at concentrations that are ?23,500 lower than that of the protein target.
  • ||||||||||  peginterferon lambda-1a (BMS-914143) / Eiger, Stanford University, Daklinza (daclatasvir) / BMS
    Trial termination, Combination therapy:  DIMENSION: Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat na (clinicaltrials.gov) -  Jun 13, 2023   
    P3,  N=453, Terminated, 
    Collectively, the present study has identified a plant-derived oligostilbene, vaticanol B, as a novel anti-HCV compound. Completed --> Terminated; Sponsor decision not based on any new unexpected safety findings or efficacy observations.
  • ||||||||||  Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Daklinza (daclatasvir) / BMS, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    Retreatment of patients experiencing failure with Hepatitis C direct-acting antivirals (Poster Area) -  Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_814;    
    Three class DAA regimens are a highly effective retreatment for HCV even in the presence of multiple NS5A and NS3 mutations. Figure: First line treatment Genotype RAS conferring reduced susceptibility Cirrhosis Re-treatment Outcome NS5A: Q30R (2) No (2) NS5A: Q30R; NS5B: D186V (1) Yes (1) SOF/VEL/VOX/RBV x 12/52 (3) SVR (3)1a (4) NS5A: Y93C (1) Pending (1) N/A PrOD/RBV x 8-12/52 (5) 1b (1) NS5A: Y93H (1) No (2) SOF/VEL/VOX x 12/52 (1) SVR (1) 1a (1) NS5A: Y93H/N, Q30E, M28V; NS3: Q80K (1) SOF/VEL/VOX/RBV x 12/52 (1) NS5A: A30K (1) NS5A: Y93H (1) SOF/VEL/VOX x 12/52 (2) SOF/DAC x 12-24/52 (4) 3 (3) NS5A: Y93H (1) No (4) SOF/VEL/VOX/RBV x 12/52 (1) SVR (4) NS5A: Q30R, K24N, M208T (1) G/P x 12/52 (1) Relapse (1) NS5A: Q30K (1) SOF/VEL/VOX x 12/52 (1) NS5A: L31V, H58D, Y93C/W (1) No (3) SOF/G/P x 16/52 (1) NS3: Q80K (1) SOF/DAC/RBV x 24/52 (1) SVR (3) NS5A: Y93C; NS3: Q80K (1) SOF/VEL x 24/52 (1) Relapse (1) Nil resistance (1) RIP (1) N/A 1a (7) Not tested (1) Yes (4) Transplant + SOF/VEL/RBV x 24/52 (1) 1b (1) NS5A: Y93H, P58A; NS3: Y56F (1) No (1) SOF/VEL/VOX x 12/52 (1) SOF/DAC x 24/52 (1)3 (2) Not tested (2) Yes (2) SOF/DAC/RBV x 24/52 (1) SOF/LDV +/- RBV x 8-12/52 (11) 4R (1) NS5B: S282C/S/T (1) No (1) SOF/G/P x 16/52 (1) SVR (5) NS5A: Y93H; NS3: Q80K (1) Yes (1) SOF/G/P x 12 weeks (1) SVR (1) NS5A: K24R; NS3: Q80K (1) No (1) SOF/VEL/VOX x 12/52 (1) SOF/VEL +/- RBV x 12/52 (3) 1a (3) Nil resistance (1) Yes (1) SOF/VEL/VOX/RBV x 12/52 (1) Relapse (2) 1a (1) NS3: Q80K (1) Yes (1) SOF/G/P x 12/52 (1) SVR (1)G/P x 8/52 (2) 3 (1) NS5A: Y93H (1) No (1) SOF/VEL/VOX x 12/52 (1) Relapse (1) DAC = daclatasvir; G/P = glecaprevir/pibrentasvir; PrOD = paritaprevir/ritonavir/ombitasvir/dasabuvir; RBV = ribavirin; SOF = sofosbuvir; SVR = sustained virological response; VEL = velpatasvir; VOX = voxilaprevir
  • ||||||||||  Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    EFFICACY OF DACLATASVIR AND LOW-DOSE SOFOSBUVIR IN TREATMENT OF HEPATITIS  () -  Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_1252;    
    Conclusions In persistent seropositive patients Daclatasvir along with low-dose Sofosbuvir are safe and effective in the treatment of chronic hepatitis C (CHC) patients with ESKD on maintenance hemodialysis. Low dose Sofosbuvir regimen can reduce the cost of treatment of HCV in ESKD patients in developing countries.
  • ||||||||||  Daklinza (daclatasvir) / BMS
    Review, Journal:  New insights from nanotechnology in SARS-CoV-2 detection, treatment strategy, and prevention. (Pubmed Central) -  Mar 25, 2023   
    Moreover, SARS-CoV-2 prevention strategies, which include the nanotechnology for upgrading personal protective equipment, facemasks, ocular protection gears, and nanopolymer-based disinfectants, have been also reviewed. This review will provide a one-site informative platform for researchers to explore the crucial role of nanomedicine in managing the COVID-19 curse more effectively.
  • ||||||||||  Daklinza (daclatasvir) / BMS
    Journal:  Novel 6-Aminoquinazolinone Derivatives as Potential Cross GT1-4 HCV NS5B Inhibitors. (Pubmed Central) -  Dec 24, 2022   
    The biological data revealed that compound 11a showed the highest activity against HCV GT1b at a micromolar concentration (EC = 0.984 µM) followed by compound 11b (EC = 1.38 µM). Both compounds 11a and 11b had high selectivity indices (SI = CC/EC), 160.71 and 71.75, respectively, which make them very interesting candidates for further development of more potent and selective anti-HCV agents.
  • ||||||||||  Review, Journal:  Biphenyls in Clusiaceae: Isolation, structure diversity, synthesis and bioactivity. (Pubmed Central) -  Dec 20, 2022   
    In this review, we summarize the progress and development in the chemistry and biological activity of biphenyls in Clusiaceae, providing an in-depth discussion of their structural diversity and medicinal potential. We also present a preliminary discussion of the biological effects with or without prenyl groups on the biphenyls.
  • ||||||||||  Daklinza (daclatasvir) / BMS, NATDAC (daclatasvir) / NATCO, Hetero
    Retrospective data, Review, Journal:  Efficacy and Safety of Sofosbuvir-based Regimens in Hepatitis C Patients With Decompensated Cirrhosis: A Systematic Review and Meta-analysis. (Pubmed Central) -  Nov 22, 2022   
    Patients on SOF/velpatasvir±ribavirin achieved a significantly higher SVR (91.0%, 95% CI: 87.7-93.9) than that of SOF/ledipasvir±ribavirin [(86.3%, 95% CI: 84.6-87.8); p=0.004)], or on SOF/daclatasvir±ribavirin (82.4%, 95% CI: 78.2-86.2%; p<0.001)...There was no publication bias. The analysis found that 12 weeks of SOF/velpatasvir without ribavirin is the preferred therapy, with a significantly higher SVR compared with other SOF-based regimens in decompensated HCV patients.
  • ||||||||||  Daklinza (daclatasvir) / BMS
    Journal:  Daclatasvir as a hepatitis C infection treatment option: an up-to-date evaluation. (Pubmed Central) -  Nov 15, 2022   
    DCV is likely to remain as a therapeutic option for the management of GT-1, GT-2, and GT-4 patients in resource limited settings, while GT-3 patients are more likely to benefit from RBV-free direct-acting antiviral combinations such as SOF/velpatasvir for 12 weeks or glecaprevir/pibrentasvir for 8 weeks. The introduction of generics for these new pan-genotypic drugs would likely eliminate the need for SOF/DCV in the near future.
  • ||||||||||  Sunvepra (asunaprevir) / BMS, Olysio (simeprevir) / J&J, Medivir, Daklinza (daclatasvir) / BMS
    Journal:  Going Viral: An Investigation into the Chameleonic Behavior or Antiviral Compounds. (Pubmed Central) -  Oct 27, 2022   
    No significant differences in size and polar surface area were observed between the DMSO- d 6 and chloroform ensembles of these three drugs. We propose that such flexible compounds are characterized as "partial molecular chameleons" and hypothesize that their ability to adopt conformations with low polar surface area contributes to their membrane permeability and oral absorption.